Management and Treatment of Patients with Chronic Hepatitis B: Towards Personalized Medicine
Open Access
Abstract
The currently available antiviral treatments (Peg-Interferon-α and Nucleos(t)ide Analogues, NA) for chronic hepatitis B (CHB) achieve a functional cure (serum HBsAg and HDV-DNA clearance) of HBV infection in a limited number of patients. Nevertheless, the continuous pharmacological suppression of viral replication by NA halts liver disease progression lowering the risk of HCC development and improving the survival. In the near future, to fully exploit the potential of old and new drugs for HBV treatment a personalized approach to the patients will be required according to an accurate definition of their virologic, immunologic and clinical profile.Keywords
This publication has 102 references indexed in Scilit:
- Efficacy of Entecavir Treatment for up to 5 Years in Nucleos(t)ide-Naïve Chronic Hepatitis B Patients in Real LifeInternational Journal of Medical Sciences, 2013
- Circulating Hepatitis B Surface Antigen Particles Carry Hepatocellular microRNAsPLOS ONE, 2012
- Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patientsHepatology International, 2012
- IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosomeJournal of Clinical Investigation, 2012
- Interferons Accelerate Decay of Replication-Competent Nucleocapsids of Hepatitis B VirusJournal of Virology, 2010
- Inhibition of Hepatitis B Virus Replication by MyD88 Involves Accelerated Degradation of Pregenomic RNA and Nuclear Retention of Pre-S/S RNAsJournal of Virology, 2010
- Interferon-inducible antiviral effectorsNature Reviews Immunology, 2008
- Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis BHepatology International, 2008
- Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis BGut, 2006
- Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapyHepatology, 1999